Costs borne by TB-affected households averted and number of households with catastrophic costs averted by infant tuberculosis vaccines (in millions)
| Country grouping | Direct medical costs borne by TB-affected households averted | Direct non-medical costs borne by TB-affected households averted | Indirect costs borne by TB-affected households averted | Total costs borne by TB-affected households averted | Number of households with catastrophic costs averted |
| All countries | 1036 (920–1143) | 2264 (2027–2509) | 2607 (2351–2896) | 5907 (5333–6533) | 3.69 (3.31–4.08) |
| High-TB burden* | 814 (707–912) | 1992 (1763–2236) | 2112 (1876–2374) | 4917 (4368–5497) | 3.32 (2.94–3.70) |
| High-TB/HIV burden* | 668 (566–764) | 1728 (1504–1967) | 1848 (1621–2097) | 4245 (3702–4807) | 2.84 (2.50–3.21) |
| High-MDR/RR-TB burden* | 783 (677–882) | 1783 (1561–2020) | 1913 (1675–2172) | 4479 (3939–5054) | 2.89 (2.53–3.27) |
| Income level† | |||||
| LIC | 181 (145–219) | 317 (270–369) | 599 (487–725) | 1096 (903–1299) | 0.61 (0.52–0.73) |
| LMIC | 699 (598–798) | 1731 (1506–1976) | 1554 (1360–1780) | 3984 (3472–4543) | 2.85 (2.50–3.25) |
| UMIC | 156 (134–179) | 217 (175–262) | 454 (334–596) | 827 (653–1030) | 0.23 (0.17–0.29) |
| World region | |||||
| AFR | 483 (399–558) | 1079 (920–1229) | 1238 (1057–1425) | 2800 (2405–3182) | 1.78 (1.55–2.01) |
| AMR | 27 (23.3–30.8) | 25.8 (23–28.7) | 27.9 (24.9–31.3) | 80.8 (72.3–89.6) | 0.01 (0.01–0.02) |
| EMR | 190 (148–234) | 302 (231–379) | 513 (391–630) | 1006 (779–1239) | 0.51 (0.38–0.65) |
| EUR | 21.9 (17.6–26.6) | 10.5 (9–12.1) | 14.9 (12.3–17.5) | 47.2 (39.1–55.8) | 0.008 (0.006–0.009) |
| SEAR | 191 (144–250) | 631 (489–800) | 513 (403–655) | 1335 (1030–1710) | 1.01 (0.80–1.28) |
| WPR | 122 (103–144) | 216 (172–263) | 300 (232–374) | 639 (512–773) | 0.37 (0.28–0.47) |
All countries include 105 low-income and middle-income countries analysed.
Values in parentheses represent equal-tailed 95% credible intervals. Total costs included patient direct medical, direct non-medical and indirect costs (all undiscounted) over 2028–2050 in 2020 US dollars. Catastrophic costs are defined as instances where the total patient costs (direct medical, direct non-medical and indirect) incurred during an episode of TB disease exceeded 20% of total annual household income.
*High-TB, high-TB/HIV (HIV-associated TB) and high-MDR/RR-TB (multidrug/rifampicin-resistant TB) burden countries as defined by the WHO.
†LIC: gross national income (GNI) per capita of US$1085 or less; LMIC: GNI per capita of US$1086–4225; UMIC: GNI per capita of US$4256–13 205.26
AFR, African region; AMR, region of the Americas; EMR, Eastern Mediterranean region; EUR, European region; LIC, low-income country; LMIC, lower middle-income country; SEAR, Southeast Asian region; TB, tuberculosis; UMIC, upper middle-income country; WPR, Western Pacific region.